Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 15/20 | 0.45 |
| ▸ | GRK2 | P25098 | 2/20 | 0.44 |
| ▸ | GRK1 | Q15835 | 2/20 | 0.44 |
| ▸ | GRK5 | P34947 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL781422 | 0.99 | PIK3CA (0.45) | PIK3CAROCK2GRK2GRK1GRK5 | |
| Tert-Butyl Formate SCHEMBL27868801 | 0.90 | PIK3CA (0.44) | PIK3CAROCK2GRK2GRK1GRK5 | |
| SCHEMBL782792 | 0.89 | PIK3CA (0.47) | PIK3CAROCK2GRK2ROCK1RPS6KB1 | |
| SCHEMBL782002 | 0.88 | ROCK2 (0.53) | PIK3CAROCK2ROCK1CYP2C9CDC42BPA | |
| SCHEMBL780665 | 0.87 | ROCK2 (0.58) | ROCK2GRK2GRK5ROCK1CYP2C9 | |
| SCHEMBL781582 | 0.87 | GRK2 (0.45) | ROCK2GRK2GRK1GRK5ROCK1 | |
| SCHEMBL782079 | 0.85 | ROCK2 (0.43) | PIK3CAROCK2GRK2GRK1GRK5 | |
| Hydrochloric Acid SCHEMBL16161572 | 0.84 | ROCK2 (0.42) | PIK3CAROCK2GRK2GRK1GRK5 | |
| SCHEMBL16161594 | 0.84 | GRK2 (0.42) | ROCK2GRK2GRK1GRK5ROCK1 | |
| SCHEMBL782436 | 0.83 | ROCK2 (0.53) | ROCK2GRK2GRK1GRK5ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3259265-B1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LTD (GB) | 2020-04-01 | — | — | EP | claimed |
| US-10144726-B2 | Modulators of the p70S6 kinase for use in the treatment of brain disorders and triple-negative breast cancer | SENTINEL ONCOLOGY LIMITED (GB) | 2018-12-04 | — | — | US | claimed |
| US-20180022735-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | claimed |
| EP-3259265-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | Sentinel Oncology Limited (GB) | 2017-12-27 | — | — | EP | claimed |
| WO-2016131776-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2016-08-25 | — | — | WO | claimed |
| EP-2435423-B1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P70S6 KINASE | SENTINEL ONCOLOGY LTD (GB) | 2014-10-15 | — | — | EP | claimed |
| CN-102459234-B | Substituted benzotriazines and quinoxalines as P70S6 kinase inhibitors | SENTINEL ONCOLOGY LTD. (GB) | 2014-10-15 | — | — | CN | claimed |
| US-8716473-B2 | Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | claimed |
| CN-102459234-A | Substituted benzotriazines and quinoxalines as P70S6 kinase inhibitors | SENTINEL ONCOLOGY LTD | 2012-05-16 | — | — | CN | claimed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | claimed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | claimed |
| EP-3259265-B1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LTD (GB) | 2020-04-01 | — | — | EP | disclosed |
| US-10144726-B2 | Modulators of the p70S6 kinase for use in the treatment of brain disorders and triple-negative breast cancer | SENTINEL ONCOLOGY LIMITED (GB) | 2018-12-04 | — | — | US | disclosed |
| US-20180022735-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180022735-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022735-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | RPS6KA1, RPS6KA3, MTOR | PIK3CA 93/4885ROCK2 374/4885GRK2 80/4885 |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | CDK1, CDK2, CDK6 | PIK3CA 194/4885ROCK2 733/4885GRK2 168/4885 |
| US-10144726-B2 | Modulators of the p70S6 kinase for use in the treatment of brain disorders and triple-negative breast cancer | RPS6KA1, RPS6KA3, MTOR | PIK3CA 93/4885ROCK2 374/4885GRK2 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.